medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2017, Number 4

<< Back Next >>

Arch Neurocien 2017; 22 (4)

Thiazine red staining is a reliable and rapid pos-mortem diagnostic tool for Alzheimer´s disease

Castellanos-Aguilar L, Martínez-Zuñiga N, Gutierrez-Murcia JL, Viramontes-Pintos A, Garcés-Ramírez L, de la Cruz F, Guadarrama-Ortíz P, Luna-Muñoz J

Language: Spanish
References: 28
Page: 33-44
PDF size: 830.21 Kb.


ABSTRACT

We have used a variety of tau immunological markers combined with the dye Thiazin red (1), an accurate marker to differentiate the fibrilar from the nonfibrillar state of both amyloid-β and tau in Alzheimer´s disease (AD). In this study, we used TR as a potential diagnostic marker of AD in unfixed brain tissue and tissue touch imprint. Control experiments included the use of thioflavin-S staining, fixed tissue, and some double-labeled material with TR and selected tau markers, including, Tau-C3, and 423. Our observation indicate that TR retains its strong affinity for both tangles and plaques neuritic plaques in frozen unfixed temporal cortex then thawed prior to tissue touch imprint. This indicates the potential for TR as a diagnostic tool for the rapid postmortem diagnosis of AD neuropathology. chemical fixation is not necessarily required for tau immunoreactivity on histological sections.


REFERENCES

  1. 1.Girych M, Gorbenko G, Maliyov I, Trusova V, Mizuguchi C, Saito H, et al. Combined thioflavin T-Congo red fluorescence assay for amyloid fibril detection. Methods Appl Fluoresc. 2016;4(3):034010. doi: 10.1088/2050- 6120/4/3/034010. PubMed PMID: 28355156.

  2. 2.Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195-203. doi: 10.1016/j.pharep.2014.09.004. PubMed PMID: 25712639.

  3. 3.Dubois B, Padovani A, Scheltens P, Rossi A, Dell'Agnello G. Timely diagnosis for Alzheimer's disease: a literature review on benefits and challenges. J Alzheimers Dis. 2016;49(3):617-31. doi: 10.3233/JAD-150692. PubMed PMID: 26484931; PubMed Central PMCID: PMCPMC4927869.

  4. 4.Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239- 59. PubMed PMID: 1759558.

  5. 5.Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16(3):271-8; discussion 8-84. PubMed PMID: 7566337.

  6. 6.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of Health and Human services task Force on Alzheimer's disease. Neurol 1984;34(7):939-44. PubMed PMID: 6610841.

  7. 7.Aboud O, Griffin WS. Silver staining of Alzheimer's disease. J Neurol Disord 2014;2(6). doi: 10.4172/2329- 6895.1000i103. PubMed PMID: 26949718; PubMed Central PMCID: PMCPMC4778739.

  8. 8.Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung. 1971;19(1):1-8. PubMed PMID: 4107507.

  9. 9.Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, et al. Morphological characterization of thioflavin- S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 2004;165(3):987-95. PubMed PMID: 15331422; PubMed Central PMCID: PMCPMC1618604.

  10. 10.Luna-Munoz J, Peralta-Ramirez J, Chavez-Macias L, Harrington CR, Wischik CM, Mena R. Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Acta Neuropathol 2008;116(5):507-15. doi: 10.1007/s00401-008-0431-x. PubMed PMID: 18810470.

  11. 11.Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248(3):111-

  12. 12.Suenaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease. J Neuropathol Exp Neurol 1990;49(1):31-40. PubMed PMID: 1688924.

  13. 13.Uchihara T. Silver diagnosis in neuropathology: principles, practice and revised interpretation. Acta Neuropathol 2007;113(5):483-99. PubMed PMID: 17401570.

  14. 14.Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis NK, et al. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 1992;83(2):170-8. PubMed PMID: 1373017.

  15. 15.Kuninaka N, Kawaguchi M, Ogawa M, Sato A, Arima K, Murayama S, et al. Simplification of the modified Gallyas method. Neuropathol 2015;35(1):10-5. doi: 10.1111/neup.12144. PubMed PMID: 25178396; PubMed Central PMCID: PMCPMC4491351.

  16. 16.Tsamis K, Mytilinaios D, Njau SN, Psaroulis D, Mavroudis J, Costa V, et al. The combination of silver techniques for studying the pathology of Alzheimer's disease. Int J Neurosci 2008;118(2):257-66. doi: 10.1080/00207450701591115. PubMed PMID: 18205081.

  17. 17.Howie AJ, Owen-Casey MP. 'Apple-green birefringence' of amyloid stained by Congo red. Kidney Int. 2012;82(1):114; author reply doi: 10.1038/ki.2012.89. PubMed PMID: 22699383.

  18. 18.Khurana R, Uversky VN, Nielsen L, Fink AL. Is Congo red an amyloid-specific dye? J Biol Chem 2001;276(25):22715-21. doi: 10.1074/jbc.M011499200. PubMed PMID: 11410601.

  19. 19.Biancalana M, Koide S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 2010;1804(7):1405-12. doi: 10.1016/j.bbapap.2010.04.001. PubMed PMID: 20399286; PubMed Central PMCID: PMCPMC2880406.

  20. 20.Santa-Maria I, Perez M, Hernandez F, Avila J, Moreno FJ. Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis 2006;9(3):279-85. PubMed PMID: 16914838.

  21. 21.Sun A, Nguyen XV, Bing G. Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J Histochem Cytochem. 2002;50(4):463-72. PubMed PMID: 11897799.

  22. 22.Rajamohamedsait HB, Sigurdsson EM. Histological staining of amyloid and pre-amyloid peptides and proteins in mouse tissue. Methods Mol Biol 2012;849:411-24. doi: 10.1007/978-1-61779-551-0_28. PubMed PMID: 22528106; PubMed Central PMCID: PMCPMC3859432.

  23. 23.Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights 2010;5:9-20. PubMed PMID: 20212918; PubMed Central PMCID: PMCPMC2832341.

  24. 24.Resch JF, Lehr GS, Wischik CM. Design and Synthesis of a Potential Affinity Cleaving Reagent for Beta-Pleated Sheet Protein Structures. Bioorg Med Chem Lett 1991;1(10):519-22. doi: Doi 10.1016/S0960-894x(01)80457-1. PubMed PMID: WOS:A1991GN27800007.

  25. 25.Mena R, Edwards P, Perez-Olvera O, Wischik CM. Monitoring pathological assembly of tau and beta-amyloid proteins in Alzheimer's disease. Acta Neuropathol 1995;89(1):50-6. PubMed PMID: 7709731.

  26. 26.Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM. Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol 1996;91(6):633-

  27. 27.Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 2007;12(4):365-75. PubMed PMID: 18198423.

  28. 28.Luna-Munoz J, Garcia-Sierra F, Falcon V, Menendez I, Chavez-Macias L, Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz- 50 antibody in Alzheimer's disease. J Alzheimers Dis 2005;8(1):29-41. PubMed PMID: 16155347.




2020     |     www.medigraphic.com